OneMedForum New York 2010, Company Presentation: Urologix, Inc. operates as a medical device company that engages in developing, manufacturing, and marketing non-surgical therapies to treat benign prostatic..Learn More at:http://www.onemedplace.com/database/list/cid/77

1. June 30, 2010 Urologix, Inc. Company Overview (NASDAQ: ULGX) for OneMedForum

3. Urologix is a medical device company that develops, manufactures and markets minimally invasive Cooled ThermoTherapy™ technology to urologists to provide a durable and effective in-office treatment for patients suffering from benign prostatic hyperplasia (BPH). Urologix, Inc.

6. Cooled ThermoTherapy (High Energy, Cooled TUMT) Temperature greater than ~50 °C is sufficient for tissue necrosis (30-40 minute treatment) *Simulation of in vivo temperature field based on Pennes bio-heat equation. Data and methods on file at Urologix, Inc. Urethral Preservation

7. The Technology behind Microwave Therapy ¹ Larson, T., et al, Detailed Interstitial Temperature Mapping During Treatment with a Novel Transurethral Microwave Thermoablation System in Patients with BPH, J of Urol. Vol 159, Jan 1998 ² Larson, T., TUMT: Comparative effects of high vs. low Temperature Treatment. Minimally Invasive Procedures in Urology, Mayo Scottsdale White Paper, April 2001 ³ Larson, B., et al, In Vivo Temperature Mapping of Prostate during Treatment with Thermatrx TMx-2000 Device: Heat Field and MRI Determinations of Necrotic Lesions, J of EndoUrology , Vol 19, Oct 2005 1 2 3

12. 350k New Potential Procedures Annually ~9,000,000 men diagnosed with BPH ~3,000,000 men on BPH drugs CAGR 3% New Drug Patients Est ~540k/Yr Urologix Expanded Market Focus 1 st Line Treatment Moderate/Obstructed Patients (est. 66%) 300k Procedures Annually Mild Moderate Severe

15. Urologix Competitive Technology View Efficacy/Durability vs. Invasiveness Invasiveness Effectiveness/Durability Placebo Urologix Drugs Laser TURP TURP TUNA Prolieve/ Thermatrx

16. Symptom Improvement: Drugs & CTT ¹Prolieve Summary of Safety and Effectiveness, P030006 ²Roehrborn, C., et al, The Effects of Combination Therapy with Dutasteride and Tamsulosin on Clinical Outcomes in Men with Symptomatic Benign Prostatic Hyperplasia: 4-Year Results for the CombAT Study, European Urology 57 (2010), p 123-131 ³Roehrborn, C., et al, 5 Year Results of a Multi-Center Trial of a New Generation Cooled TUMT for BPH, Abstract 2122, AUA 2009 Annual Convention Note: The data for Cooled ThermoTherapy and pharmaceuticals was not collected in a head-to-head study. Direct comparisons cannot be made.

17. Peak Urinary Flow Rates ¹Prolieve Summary of Safety and Effectiveness, P030006 ²Roehrborn, C., et al, The Effects of Combination Therapy with Dutasteride and Tamsulosin on Clinical Outcomes in Men with Symptomatic Benign Prostatic Hyperplasia: 4-Year Results for the CombAT Study, European Urology 57 (2010), p 123-131 ³Roehrborn, C., et al, 5 Year Results of a Multi-Center Trial of a New Generation Cooled TUMT for BPH, Abstract 2122, AUA 2009 Annual Convention Note: The data for Cooled ThermoTherapy and pharmaceuticals was not collected in a head-to-head study. Direct comparisons cannot be made.

19. 5 Year Visit Accountability C. Roehrborn, L. Mynderse, A. Partin, G. Preminger, E. Cote, S. Madej: Results of a Multi-Center Trial of a New Generation Cooled TUMT for BPH, Abstract #2122, AUA 2009

24. Fiscal Year 2009 First 9 Months FY2010 Revenue $12.8M $11.5M Gross Margin 50% 56% OpEx $10.9M $8.0M Net (Loss) $(4.4M) $(1.5M)

26. Stryker Warren, Jr. Chief Executive Officer 763.475.7605 [email_address] Brian Smrdel Chief Financial Officer 763.475.7696 [email_address] Contacts: Greg Fluet EVP & Chief Operating Officer 763.475.7690 [email_address]